Loading
AN2 Therapeutics
A listed US company making boron-based medicines. Its cancer work is a pill called epetraborole for polycythaemia vera, a slow blood cancer that makes too many red blood cells, plus two early laboratory programmes for solid tumours.
Also called: AN2 Therapeutics, Inc.
Overview
AN2 Therapeutics develops small molecules built on boron chemistry across infectious disease and oncology. Its pipeline page lists epetraborole, an oral small molecule it describes as acting on globin synthesis, at Phase 2 in polycythaemia vera, and the company says it is designed to lower haematocrit without broadly suppressing white cells or platelets. The Phase 2 study in phlebotomy-dependent polycythaemia vera (NCT07891533, EBO-PV-201) was registered as not yet recruiting, with an estimated start in November 2026. The same drug is also in development for lung infections (M. abscessus, melioidosis), and a separate compound, AN2-502998, is in development for Chagas disease. Two oncology research programmes are listed as preclinical: a PI3K-alpha inhibitor the company says is selective for kinase- and helical-domain PIK3CA mutants over wild-type PI3K-alpha, and boron-based ENPP1 inhibitors intended to restore innate immune signalling in tumours. AN2 is listed on Nasdaq under ANTX according to its SEC filings.
Headquarters
Menlo Park, CA, US
Scorecard
All companies#706of 1706 companies, score 3
- phase 1/2 +1
- modalities +2
0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsPublic
Investors
Type
Biotech · NASDAQ: ANTX
Stage
Public
Website
Products
1Phase 2Small molecule, oral (boron-based)
Epetraborole is an experimental pill from AN2 Therapeutics, with a phase 2 trial due to start for polycythaemia vera.
Notes
- Founding year not read from a primary source, so omitted.
- No AN2 trial in OnCo yet: NCT07891533 (epetraborole in polycythaemia vera, Phase 2, not yet recruiting) was confirmed through the ClinicalTrials.gov v2 API.
- The PI3K-alpha and ENPP1 programmes are preclinical and unnamed; ENPP1 has no target id in OnCo.
Connected
6Similar pages
- CompanyTerremoto Biosciences
Shares RA Capital Management, PIK3CA / PI3K-alpha.
cancers
fronts
targets
drugs
Phase 2Small molecule, oral (boron-based)
companies
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
an2therapeutics.com · 3
ClinicalTrials.gov · 1
racap.com · 1
sec.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/